PrSandozⓇ Sitagliptin and PrSandoz® Sitagliptin-Metformin are indicated as monotherapy or as add-on therapy for adults with type 2 diabetes to improve glycemic control.
With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.
BOUCHERVILLE, Quebec, Jan. 06, 2023 (GLOBE NEWSWIRE) — Today, Sandoz Canada announced the launch of PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin.
Monotherapy: These products are indicated as an additional therapy to improve glycemic control in adult patients with type 2 diabetes mellitus for whom current existing therapy, along with diet and exercise, does not provide adequate glycemic control. It is also used to help reduce long-term complications associated with the disease and help maintain quality of life over time.
Add-on combinations: PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin are indicated as an adjunct to diet and exercise in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with:
Metformin (PrSandoz® Sitagliptin)
A sulfonylurea
Pioglitazone
Premixed or long/intermediate acting insulin
PrSandozⓇ Sitagliptin is available in strengths of 25mg (bottle of 100 tablets), 50mg (bottle of 100 tablets), and 100mg (bottle of 100 and 500 tablets).
PrSandozⓇ Sitagliptin-Metformin is available in strengths of 50mg/500mg (bottle of 60 and 500 tablets), 50mg/850mg (bottle of 60 and 360 tablets), and 50mg/1000mg in strength (bottle of 60 and 360 tablets).
“With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products”, says Michel Robidoux, President and General Manager of Sandoz Canada.
® Registered trademark owned or used under licence by Sandoz Canada Inc.
Disclaimer
This press release contains forward-looking statements, including, but not limited to, potential future revenues from the sale of PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin. You should not place undue reliance on these statements. These forward-looking statements reflect management’s current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results could differ materially from those set forth in the forward-looking statements. There can be no assurance that PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin will be submitted or approved for other additional indications or labelling in other markets, or at any particular time, nor can it be guaranteed that PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin will be approved by a regulatory body or will be commercially successful in the future. In particular, management’s expectations regarding PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin could be affected by a number of factors, including: uncertainties inherent in research and development, including unexpected clinical study results and additional analysis of existing clinical data; unexpected regulatory actions, delays or government regulations in general; the company’s ability to obtain or maintain intellectual property protection; general economic and industry conditions; the global trend towards streamlining healthcare costs, including constant pressure regarding pricing; impacts of the COVID-19 pandemic; unexpected manufacturing problems, and other risks and factors mentioned in form 20-F filed by Novartis AG with the US Securities and Exchange Commission. Sandoz is providing the information in this media release as of today and does not undertake any obligation to update any forward-looking statements described herein as a result of new information, future events or otherwise, except as required by law.
About Sandoz
Sandoz International GmbH is a world leader in generics and biosimilars and a division of the Swiss multinational Novartis.
Sandoz Canada is a pioneer, a leader and trusted supplier of quality generics and biosimilars with over 65 million prescriptions per year, based on decades of global experience and capabilities in the development, manufacturing and commercialization of its products. Sandoz launched the first biosimilar in Europe in 2006 and in the Canadian market in 2009.
www.sandoz.ca
Follow us on LinkedIn: https://www.linkedin.com/company/sandoz-canada/
Contact:
Marie-Soleil Pepin
Sandoz Canada Inc.
marie-soleil.pepin@sandoz.com / communications.canada@sandoz.com
The Food and Drug Administration on Friday approved Eisai and Biogen’s Alzheimer’s treatment lecanemab, clearing the way for the drug to be prescribed to patients and opening what will likely be a long debate over whether Medicare will pay for it. The approval comes eighteen months after the FDA approved Eisai (ticker: ESALY ) and Biogen ‘s ( BIIB ) other Alzheimer’s drug Aduhelm.
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Atai Life Sciences (NASDAQ: ATAI)-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants' MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo. MADRS is a widely used clinician‐rated measure of depressive severity. The Phase 2a proof-of-concept trial was a two-week, randomized, double-blind, placebo-controlled multi-center study
If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks.
Biogen stock was halted Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, lecanemab.
MARKET PULSE Shares of Casi Pharmaceuticals Inc. (CASI) were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics.
If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.
Moderna (NASDAQ: MRNA) was once a stock market champion. Shares of the biotech company soared more than 400% back in 2020 as investors bet on its ability to win the coronavirus vaccine race. Let's check out why Moderna is a buy in the new year.
A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.
Bellerophon Therapeutics Inc (NASDAQ: BLPH) entered into a license agreement for the development and commercialization of INOpulse with Baylor BioSciences. Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million. Additionally, Bellerophon is entitled to royalties of 5% on net sales resulting from all licensed INOpulse indications within Greater China. Baylor BioSciences will receive exclusive rights to develop and commercialize INOpulse within Greater C
Is Merck stock a buy after Moderna said adding its cancer vaccine to Keytruda reduced the risk of relapse? Is MRK stock a buy now?
Is Moderna stock a buy after the company offered a promising update for its cancer vaccine? Is MRNA stock a buy right now?
Shares of biotech BioVie (NASDAQ: BIVI) rose 15.3% in December, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock jumped after the company announced on Dec. 5 that its candidate therapy NE3107 had shown positive results in studies on both Parkinson's disease and Alzheimer's disease. In one of the phase 2 trials, 88.9% of Parkinson's disease patients 70 or older who were treated with NE3107 in combination with levodopa (the current standard of care for Parkinson's) showed improvements of greater than 30% on their UPDRS Part 3 score — a key measurement of motor function — compared to just 63.6% of patients treated with levodopa alone.
Chinese drugmaker CanSino Biologics started trial production of a vaccine using mRNA Technology to target new variants of Covid-19 that are behind the country’s current outbreak.
Inventiva (NASDAQ: IVA) has decided to modify the clinical development plan of lanifibranor for non-alcoholic steatohepatitis (NASH). The changes follow a consultation with the FDA, Inventiva said.* Inventiva had initially designed a two-part study where part one would support accelerated approval with data from 900 patients, and part two would follow 2,000 patients for up to seven years. The company is now replacing part 2 with a new, separate Phase 3 trial that will enroll around 800 patients
How effective is Wegovy for weight loss? What to know about who is eligible, how it works, cost, side effects and insurance coverage as drug shortage ends.
After releasing topline late-stage clinical trial data on its drugs effect on a set of precancerous conditions, a longtime Bay Area biotech said it plans to raise $175 million through a stock sale. Geron Corp. (NASDAQ: GERN) said early Wednesday that its drug, called imetelstat, met the primary efficacy goal in a Phase III study in certain patients with myelodysplastic syndromes, or MDS. The company said it will submit the data to the Food and Drug Administration as it asks the agency this year to approve the drug.
ModernaCEO Stephane Bancel doesn't see much of a market for the company's mRNA-based vaccine for mpox (formerly called "monkeypox") despite "fantastic" preclinical data.
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Walgreens Boots Alliance Inc (NASDAQ: WBA) is reportedly the first major national pharmacy chain to say it plans to dispense the abortion pill under the FDA's new rules. Tuesday, the FDA said it would allow pharmacies to offer abortion pills, mifepristone, in the U.S. Pharmacies must complete a form for certification to distribute the abortion pills. Any pharmacy to become certified to dispense mifepristone, an FDA-approved medication for use up to 10 weeks in pregnancy. Other companies that may